NVO
Novo Nordisk A/S
NVO has the edge over ORGO overall, supported by stronger fundamentals and lower modeled downside.
ORGO
Organogenesis Holdings Inc.
ORGO offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
ORGO Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Under pressure | |
| Strong |
ORGO's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
ORGO PE Valuation
ORGO has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
ORGO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| Strongly weakening | |
| Limited | |
| Moderate |
Analysts expect ORGO's losses to shrink, with revenue declining.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over ORGO on earnings quality, reporting a profit while its opponent remains loss making.
ORGO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.15 | -$1.04 |
| Q2 2026 | -$0.79 | -$0.66 |
| Q1 2026 | -$0.12 | +$0.04 |
| Q4 2025 | $0.15 | +$0.16 |
| Q3 2025 | -$0.11 | -$0.05 |
| Q2 2025 | -$0.13 | $0.00 |
| Q1 2025 | -$0.16 | -500% |
| Q4 2024 | -$0.01 | -125% |
ORGO lost $1.15 per share over the past year, and its loss has widened in each of the last three quarters.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over ORGO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over ORGO on profitability, with a higher operating margin.
ORGO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $45.5M | -70% |
| Q2 2026 | $43.8M | -57% |
| Q1 2026 | $37.2M | -57% |
| Q4 2025 | $225.6M | +78% |
| Q3 2025 | $150.9M | +31% |
| Q2 2025 | $101M | -22% |
| Q1 2025 | $86.7M | -21% |
| Q4 2024 | $126.7M | +27% |
ORGO's revenue is shrinking: $45M last quarter, down 70% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -65% | -79 points |
| Q2 2026 | -117% | -104 points |
| Q1 2026 | -185% | -154 points |
| Q4 2025 | 28% | +20 points |
| Q3 2025 | 14% | +8.3 points |
| Q2 2025 | -12% | -1.8 points |
| Q1 2025 | -31% | -27 points |
| Q4 2024 | 8.1% | +9.3 points |
ORGO's operating margin was −65% last quarter, down 79 points from the same quarter a year ago, near the bottom of its range since 2019.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over ORGO on cash generation, producing positive trailing cash flow while its opponent burns cash.
ORGO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$20.1M | -2477% |
| Q2 2026 | -$32.8M | +$3.8M |
| Q1 2026 | $18M | +$41.5M |
| Q4 2025 | $34.8M | +359% |
| Q3 2025 | $844K | -86% |
| Q2 2025 | -$36.5M | -1378% |
| Q1 2025 | -$23.6M | -$11.2M |
| Q4 2024 | $7.6M | +3.9% |
ORGO's free cash flow was −$64,000 over the past year, against −$52M the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has 4.4B diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
ORGO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +316K shares |
| 1 year | -1.4% | -1.9M shares |
| 3 years | -3.3% | -4.4M shares |
| 5 years | -3.6% | -4.9M shares |
| Available history | +39% | +36.2M shares |
ORGO has the edge over NVO on shareholder dilution, with a more favorable share count trend.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
ORGO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -4.9x | Net Cash |
| Q4 2025 | -1.6x | Net Cash |
| Q3 2025 | -9.9x | Net Cash |
| Q4 2024 | -10.2x | Net Cash |
| Q3 2024 | -13.6x | Net Cash |
| Q2 2024 | -6.0x | Net Cash |
| Q1 2024 | -0.8x | Net Cash |
| Q4 2023 | -1.3x | Net Cash |
ORGO has the edge over NVO on leverage, with a lower net debt burden relative to earnings.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
ORGO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 27.3 | Oversold |
| Stochastic | 7.8 | Oversold |
ORGO's weekly RSI is 27 (oversold) and its Stochastic is 8 (oversold).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
ORGO PE vs Healthcare Sector
| Metric | ORGO | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ORGO has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over ORGO on trend strength, trading above more of its moving averages.
ORGO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.07 | 10% below |
| 20 week MA | $1.63 | 41% below |
| 50 week MA | $2.60 | 63% below |
| 100 week MA | $3.40 | 72% below |
| 200 week MA | $3.18 | 70% below |
ORGO is in a downtrend: it's below all five of its weekly moving averages, and 70% below its 200-week average.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over ORGO on returns for 2026, with the stronger performance.
ORGO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $4.94 | $6.46 | +31% |
| 2021 | $6.46 | $10.2 | +58% |
| 2022 | $10.2 | $2.59 | -75% |
| 2023 | $2.59 | $4.09 | +58% |
| 2024 | $4.09 | $3.19 | -22% |
| 2025 | $3.19 | $5.28 | +66% |
| 2026 YTD | $5.28 | $0.96 | -82% |
ORGO is down 82% so far in 2026, after finishing higher in four of the previous six years.